Chief Science Officer describes compelling preclinical data supporting continued development of PLACCINE as a differentiated, next-generation vaccine modality LAWRENCEVILLE, N.J.,…
- In NHP, four monthly doses of 20 mg/kg of PGN-EDO51 resulted in 34.9% exon skipped transcripts in biceps; a…
BRIDGEWATER, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical…
NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and…
NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced that…
CHICAGO, March 22, 2023 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company focused on discovering and developing next-generation medicines that…
Collaboration Will Leverage Data Analytics and AI to Accelerate Clinical Trial ExecutionMORRISVILLE, N.C., March 22, 2023 (GLOBE NEWSWIRE) -- Syneos…
Former Reliq Health Technologies Chief Innovation Officer and veteran product leader brings over a decade of experience building and commercializing…
Achieved clinical validation of PRISM platform in 2022 – demonstrated ability to potently and durably engage RNA targets and translate…
ROCKVILLE, Md., March 22, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the…